Programs address the need for disease-modifying therapies targeting root causes of fibrosis Funding will support ... other CCN family members, including CTGF/CCN2 and WISP1/CCN4, on multiple ...

Programs address the need for disease-modifying therapies targeting root causes of fibrosis Funding will support ... other CCN family members, including CTGF/CCN2 and WISP1/CCN4, on multiple ...

In MASLD and MASH, TGF-β signaling contributes to hepatocyte lipid accumulation, cell death and fibrosis progression through both Smad and non-Smad pathways. In HCC, TGF-β and other TGF-β-SF cytokines ...

Emerging evidence suggests a role for PI3K/mTOR signalling in the pathology of organ fibrosis ... signalling in response to TGF-β 1 stimulation of primary human lung fibroblasts (HLFs), and to ...

including CTGF/CCN2 and WISP1/CCN4, on multiple cell types contributing to the fibrotic pathology. This approach is an evolution from blocking individual CCN proteins and their upstream activator, TGF ...

Introduction: Renal fibrosis ... pathway. Experimental validation further confirmed that YQQRG suppressed the PI3K/AKT pathway in the renal tissues of UUO mice; the addition of the PI3K/AKT agonist ...

This pathway may present a promising target for new therapeutic interventions in SSc. Previous studies have shown that PEDF is highly expressed in idiopathic pulmonary fibrosis and is inducible by TGF ...

Thomas H. Sisson, Toby M. Maher, Iyabode O. Ajayi, Jessie E. King, Peter D.R. Higgins, Adam J. Booth, Rommel L. Sagana, Steven K. Huang, Eric S. White, Bethany B ...

Munich, Germany – April 9, 2025-- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced its ...

The FDA has cleared a next-generation continuous glucose monitor with a 15-day sensor wear time, according to an industry press release. Adults who develop new-onset type 2 diabetes may have ...